近日，广东省发布"十五五"规划建议，明确要"做强医疗器械等优势产业"，"推动生物制造、脑机接口 等成为新的经济增长点"。 "十四五"期间，我国医疗装备产业实现跨越式发展，年复合增长率约10.7%。在技术攻坚与政策支持的 双重助力下，高端医疗器械从"跟跑"向"并跑" 加速迈进，部分领域实现"领跑"突破。 这一成果的背后，有一家关键机构为推动中国医疗器械产业高质创新发挥了重要作用，这家机构便是 2020年4月经工业和信息化部批复成立的国家高性能医疗器械创新中心（以下简称"国创中心"），其也 是全国医疗器械领域唯一的国家级制造业创新中心。 该中心为由龙头企业、高校、科研院所组成的"攻关+创新+转化"联合体，近年来不仅携全球首台5.0T人 体全身磁共振、国产首台ECMO等跻身国际第一梯队的创新装备，实现了系列关键技术突破，更为国内 培育了一批前沿创新医疗（002173）器械企业。 "医疗器械涉及多学科交叉，技术复杂度高，让中小企业独立掌控全链条技术与资源，不仅负担沉重， 创新效率也极低。国创中心的核心价值之一，就是打造'技术创新与转化的热带雨林生态'，为企业提供 公共技术支撑，解决临床验证、标准制定、安全评估等共性问 ...

"信心有数"栏目 南方都市报、南都大数据研究院"信心有数"栏目，用数据记录广东实现现代化的奋进之路，用数据描绘 万马奔腾共创美好的活力之路，用数据书写每一个你我昂扬向上的信心之路。 千里之行，系于你我；心中有数，广东可期。 12月3日，广东省政府新闻办召开"'十四五'广东成就"系列主题新闻发布会，"六个继续领先""六个跃升 前列"的亮眼成绩，清晰勾勒出广东科技创新步步坚实的足迹。南都大数据研究院本期"信心有数"带你 一同走近这份扎实的"科技成绩单"，看广东如何以实实在在的作为，推动科技向前迈进。 广东科技硬核出列 从"六边形战士"到"前沿开拓者" 先看"十四五"期间广东科技成果有多"能打"！研发经费、高新技术企业数、发明专利有效量、PCT国际 专利申请量、高技术制造业营收、高技术产品出口，六大核心指标全部拿下全国第一，妥妥的"六边形 战士"。2024年研发经费飙至5100亿元，年均增长近10%，占全国14%；高新技术企业超7.7万家，占全 国15.4%；发明专利有效量较2020年翻番，PCT 国际专利申请量、高技术制造业营收和出口均占全国三 分之一份额，实力碾压级领跑。 如果说稳是发展的底气，那么跃升就是持续 ...

Core Viewpoint - The announcement from United Imaging Healthcare regarding the employee stockholding platform's plan to reduce its holdings indicates a significant liquidity need, with a potential cash-out of approximately 1.78 billion yuan from the sale of up to 13.38 million shares, representing 1.62% of the total share capital [1][2][3] Group 1: Employee Stockholding and Share Reduction - The employee stockholding platform plans to reduce its holdings due to funding needs, as some employees have requested to sell their shares [2] - This is not the first reduction; the platform previously sold 7.47 million shares for 894 million yuan in July of the previous year [2] - The reduction comes shortly after the company has shown signs of recovery from a performance low in 2024, where it faced its first revenue and net profit decline since its IPO [1][3] Group 2: Financial Performance and Market Position - In 2024, United Imaging Healthcare reported a revenue of 10.3 billion yuan, a year-on-year decrease of 9.73%, and a net profit of 1.26 billion yuan, down 36.08% [3] - The company's gross margin was 48.54%, significantly lower than its competitor Mindray Medical's 63.11%, and its net profit margin was 12.06%, compared to Mindray's 36.3% [3] - By the first quarter of 2025, the company achieved a revenue of 2.48 billion yuan, a year-on-year increase of 5.42%, and a net profit of 370 million yuan, a slight increase of 1.87% [3] Group 3: Leadership and Company Background - United Imaging Healthcare was founded in 2011 and went public in 2022, with its actual controller being Xue Min, who has seen a significant decrease in personal wealth from 35.3 billion yuan in 2023 to 24.94 billion yuan in 2025 [4][5] - Xue Min is recognized as a pioneer in China's medical imaging field, having previously developed the country's first 1.5T superconducting MRI system [4][5] - The company has established a strong market presence through innovation and government support, launching several groundbreaking products [5] Group 4: Current Market Valuation - As of August 6, the stock price of United Imaging Healthcare was 128.55 yuan per share, with a market capitalization of 105.9 billion yuan, reflecting a significant decline from its peak valuation of over 170 billion yuan [6]